| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.13.6.577 |
| P698 | PubMed publication ID | 15174947 |
| P2093 | author name string | Nabil Saba | |
| Michel Vulfovich | |||
| P2860 | cites work | p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells | Q24315152 |
| Cyclooxygenase regulates angiogenesis induced by colon cancer cells | Q24336248 | ||
| A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants | Q24339624 | ||
| Humanization of an anti-p185HER2 antibody for human cancer therapy | Q24561842 | ||
| Thalidomide is an inhibitor of angiogenesis | Q24563363 | ||
| Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia | Q24599829 | ||
| Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer | Q24673693 | ||
| Continuous cultures of fused cells secreting antibody of predefined specificity | Q26776979 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Protein modules and signalling networks | Q27860694 | ||
| Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 | ||
| Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors | Q28118852 | ||
| Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer | Q28138355 | ||
| Sulindac inhibits activation of the NF-kappaB pathway | Q28162606 | ||
| A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene | Q28279136 | ||
| Epidermal growth factor-related peptides and their receptors in human malignancies | Q28293442 | ||
| Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok | Q28302094 | ||
| Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation | Q36556010 | ||
| Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. | Q36572588 | ||
| Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | Q36641362 | ||
| Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity | Q37108753 | ||
| Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers | Q37220614 | ||
| Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents | Q37472121 | ||
| Molecular themes in oncogenesis | Q37625792 | ||
| ras oncogenes: their role in neoplasia | Q37819681 | ||
| Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity | Q38288609 | ||
| Expression of vascular endothelial growth factor in renal cell carcinomas | Q38464910 | ||
| Monoclonal antibodies for treating cancer | Q38686386 | ||
| Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. | Q39444763 | ||
| Maytansine | Q39785130 | ||
| KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas | Q40554859 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy | Q40634072 | ||
| The Ras signal transduction pathway | Q40733281 | ||
| Radiolabeled monoclonal antibodies | Q40930421 | ||
| Radioimmunotherapy: recent results and future directions | Q40945426 | ||
| Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies | Q41055451 | ||
| A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells | Q41098690 | ||
| The promise and pitfalls of monoclonal antibody therapeutics | Q41238858 | ||
| Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses | Q41262871 | ||
| Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton | Q41462575 | ||
| Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability | Q41510749 | ||
| A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. | Q41615181 | ||
| Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions | Q41658552 | ||
| Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing | Q41705080 | ||
| Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. | Q41740883 | ||
| Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome | Q41743756 | ||
| Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. | Q42827718 | ||
| Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. | Q35409847 | ||
| Principles of antibody therapy | Q35660057 | ||
| Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis | Q35742409 | ||
| Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway | Q35952074 | ||
| Antiangiogenic gene therapy | Q36069788 | ||
| Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer | Q36292182 | ||
| The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors | Q36334739 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | Q42971644 | ||
| Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q43565576 | ||
| Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. | Q43584710 | ||
| Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial | Q43615357 | ||
| Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | Q43648034 | ||
| Deep venous thrombosis and thalidomide therapy for multiple myeloma | Q43648440 | ||
| Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients | Q43660475 | ||
| The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications | Q43700541 | ||
| Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome | Q43715004 | ||
| Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study | Q43797374 | ||
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study | Q43904522 | ||
| Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma | Q43915145 | ||
| Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). | Q44071979 | ||
| Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. | Q44189620 | ||
| Signaling vascular morphogenesis and maintenance | Q45058276 | ||
| Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model | Q45865348 | ||
| Suppression of tumor growth through disruption of hypoxia-inducible transcription | Q45872806 | ||
| Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. | Q45958891 | ||
| Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs | Q46227342 | ||
| Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders | Q47614258 | ||
| Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. | Q47685354 | ||
| CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor | Q47722565 | ||
| Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide | Q47808995 | ||
| Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade | Q47956962 | ||
| Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. | Q50888945 | ||
| Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. | Q53390272 | ||
| Cooperating oncogenes converge to regulate cyclin/cdk complexes. | Q53445613 | ||
| Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. | Q53994746 | ||
| The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. | Q54115075 | ||
| Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. | Q55476886 | ||
| Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia | Q59059621 | ||
| Fused transcript of abl and bcr genes in chronic myelogenous leukaemia | Q59064021 | ||
| Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia | Q59085791 | ||
| Prevalence of ras gene mutations in human colorectal cancers | Q59088716 | ||
| Isolation of putative progenitor endothelial cells for angiogenesis | Q28302884 | ||
| PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs | Q28343682 | ||
| Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | Q28370451 | ||
| Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers | Q28375856 | ||
| A role for hematopoietic stem cells in promoting angiogenesis | Q28508896 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| The biology of vascular endothelial growth factor | Q29615946 | ||
| The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis | Q29616121 | ||
| Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 | Q29617346 | ||
| Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis | Q29617644 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas | Q29620630 | ||
| Development of matrix metalloproteinase inhibitors in cancer therapy. | Q31832006 | ||
| Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. | Q31929753 | ||
| Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors | Q31960434 | ||
| Lipoxygenase-5 is overexpressed in prostate adenocarcinoma | Q32159450 | ||
| Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance | Q33328103 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin's lymphoma | Q33337993 | ||
| Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study | Q33342242 | ||
| A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 | ||
| Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia | Q33499555 | ||
| Advances in cancer immunotherapy | Q33546850 | ||
| Epidermal growth factor receptors: critical mediators of multiple receptor pathways | Q33597368 | ||
| Chronic myeloid leukemia | Q33603077 | ||
| The biology of chronic myeloid leukemia | Q33686190 | ||
| The epidermal growth factor receptor and its inhibition in cancer therapy | Q33716127 | ||
| Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 | ||
| Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents | Q33818571 | ||
| Cancer chemoprevention: progress and promise | Q33837298 | ||
| Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization | Q33870103 | ||
| Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 | ||
| Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents | Q33914337 | ||
| Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor | Q33941495 | ||
| Target antigens for prostate cancer immunotherapy. | Q33944182 | ||
| Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy | Q33944186 | ||
| Monoclonal antibody therapy for solid tumors | Q33982804 | ||
| A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis | Q33995709 | ||
| Development of inhibitors for protein tyrosine kinases | Q34103669 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents | Q34112979 | ||
| ZD1839 ('Iressa') as an anticancer agent | Q34112985 | ||
| Antibody-targeted immunotherapy for treatment of malignancy | Q34131950 | ||
| Redefining the target: chemotherapeutics as antiangiogenics | Q34142103 | ||
| Receptors for epidermal growth factor and other polypeptide mitogens | Q34163558 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis | Q34210479 | ||
| Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. | Q34280682 | ||
| Angiogenesis and antiangiogenic approaches to sarcomas | Q34295160 | ||
| The role of cyclooxygenase-2 in prostate cancer | Q34335675 | ||
| Proteasome inhibitors: from research tools to drug candidates | Q34341985 | ||
| Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors | Q34349062 | ||
| Her-2/neu and breast cancer | Q34365892 | ||
| Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. | Q34386601 | ||
| Eradication of large colon tumor xenografts by targeted delivery of maytansinoids | Q34389426 | ||
| Tyrosine kinase inhibitors-ZD1839 (Iressa). | Q34416857 | ||
| Epidermal growth factor receptor biology (IMC-C225). | Q34416870 | ||
| Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse | Q34418299 | ||
| Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials | Q34461569 | ||
| Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts | Q34482756 | ||
| Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. | Q34507119 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications | Q34523149 | ||
| Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 | ||
| Imatinib mesylate--a new oral targeted therapy | Q34547382 | ||
| Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma | Q34570747 | ||
| Mechanism of activation of a human oncogene | Q34708285 | ||
| Thalidomide and immunomodulatory drugs as cancer therapy | Q34985267 | ||
| Molecular mechanisms of novel therapeutic approaches for multiple myeloma | Q35013215 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular design | Q55213915 |
| P304 | page(s) | 577-607 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Molecular biological design of novel antineoplastic therapies | |
| P478 | volume | 13 |
Search more.